GSK plc (NYSE:GSK) is one of the best affordable healthcare stocks to buy now. GSK plc (NYSE:GSK) announced on December 19 an ...

The GSK-3 inhibitor market is gaining momentum, not due to older drugs like lithium, but rather to newer, more targeted programs currently in mid- and late-stage development. These could change how ...

With a fresh endorsement from the FDA, the last of five major drug approvals has fallen into place for GSK in 2025. | Tuesday ...

Different isoforms of glycogen synthase kinase-3 (GSK-3) have been linked to Alzheimer disease (AD). The β variant is one of several kinases that phosphorylate the microtubule-associated protein tau ...

T-cell acute lymphoblastic leukemia (T-ALL) accounts for ~15% of pediatric and 25% of adult cases of ALL. Progress in T-ALL therapy has been impressive, with cure rates approaching 80% for children ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation unjustified, leading to a "Strong Buy" rating. The company’s diversified portfolio ...

Respiratory syncytial virus, or RSV, is prevalent and potentially deadly, and the lack of any vaccines for the pathogen underscores a global unmet medical need. A GSK vaccine candidate for the virus ...

Hal Barron, MD, who will become CEO and co-chair of Altos Labs. He is now GlaxoSmithKline (GSK)’s President of R&D and Chief Scientific Officer, GlaxoSmithKline (GSK) has agreed to acquire Affinivax ...

Haleon, formerly the consumer health business of GSK, began life as a standalone entity Monday after its spinoff from the British drugmaker. The de-merger marked the completion of a long-awaited ...

GSK’s respiratory syncytial virus (RSV) vaccine has hit the mark in a phase 3 trial in older adults, teeing the company up to file for approval by the end of the year. But the data-devoid statement ...

Hopes of a quick fix for GlaxoSmithKline’s respiratory syncytial virus (RSV) vaccine woes are fading fast. Having voluntarily paused three maternal RSV vaccine clinical trials 10 days ago, GSK has now ...